Literature DB >> 8144986

Phase I/II trial of preoperative thermoradiotherapy in the treatment of urinary bladder cancer.

S I Masunaga1, M Hiraoka, K Akuta, Y Nishimura, Y Nagata, S Jo, M Takahashi, M Abe, T Terachi, K Oishi.   

Abstract

Between April 1984 and September 1988, preoperative radiotherapy or thermoradiotherapy was administered to 49 patients with bladder cancer (T1-4N0M0; UICC classification, 1987). Twenty-one patients were preoperatively treated by radiotherapy alone, with 4 Gy per fraction and three fractions per week to a total dose of 24 Gy (TDF = 53, group 1). The other 28 patients were treated by the same radiotherapy regimen in combination with hyperthermia (group 2). Regional hyperthermia was administered for 35-60 min immediately after irradiation (two sessions per week to a total of four sessions) using an 8 MHz RF capacitive heating device. Group 2 was divided into group 2 (high), in which the average intravesical temperature (T(av)) was > 41.5 degrees C, which was the mean value, and group 2 (low) with a T(av) < 41 x 5 degrees C. Group 2 (high) showed a significantly higher incidence of down-staging and tumour degeneration than both group 1 and group 2 (low). In addition, the local recurrence rate was lower and survival time was longer in group 2 than in group 1, although not significantly so. In particular, the patients with T3-4 or grade 3 bladder cancer in group 2 had a longer average survival than those in group 1, although the difference was not significant. The toxicity associated with hyperthermia was pain during treatment, and complications were not serious.

Entities:  

Mesh:

Year:  1994        PMID: 8144986     DOI: 10.3109/02656739409009329

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  8 in total

Review 1.  Heating technology for malignant tumors: a review.

Authors:  H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

Review 2.  A systematic review of regional hyperthermia therapy in bladder cancer.

Authors:  Thomas A Longo; Ajay Gopalakrishna; Matvey Tsivian; Megan Van Noord; Coen R Rasch; Brant A Inman; Elisabeth D Geijsen
Journal:  Int J Hyperthermia       Date:  2016-05-01       Impact factor: 3.914

Review 3.  Overview of bladder heating technology: matching capabilities with clinical requirements.

Authors:  Paul R Stauffer; Gerard C van Rhoon
Journal:  Int J Hyperthermia       Date:  2016-03-04       Impact factor: 3.914

Review 4.  Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Authors:  Jan C Peeken; Peter Vaupel; Stephanie E Combs
Journal:  Front Oncol       Date:  2017-06-30       Impact factor: 6.244

Review 5.  Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses.

Authors:  Niloy R Datta; H Petra Kok; Hans Crezee; Udo S Gaipl; Stephan Bodis
Journal:  Front Oncol       Date:  2020-06-12       Impact factor: 6.244

Review 6.  Clinical Evidence for Thermometric Parameters to Guide Hyperthermia Treatment.

Authors:  Adela Ademaj; Danai P Veltsista; Pirus Ghadjar; Dietmar Marder; Eva Oberacker; Oliver J Ott; Peter Wust; Emsad Puric; Roger A Hälg; Susanne Rogers; Stephan Bodis; Rainer Fietkau; Hans Crezee; Oliver Riesterer
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

Review 7.  Avoiding Pitfalls in Thermal Dose Effect Relationship Studies: A Review and Guide Forward.

Authors:  Carolina Carrapiço-Seabra; Sergio Curto; Martine Franckena; Gerard C Van Rhoon
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

8.  Intensity-Modulated Radiotherapy with Regional Hyperthermia for High-Risk Localized Prostate Carcinoma.

Authors:  Sota Nakahara; Takayuki Ohguri; Sho Kakinouchi; Hirohide Itamura; Takahiro Morisaki; Subaru Tani; Katuya Yahara; Naohiro Fujimoto
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.